Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
SELL! SELL! ... I just heard ...
... it's not GOLD but yellow confetti ... and not OIL but really, really old bacon grease! Can't believe I bought this POS!
LOL ...!!!
Hoo-Yaa!!! ... the fuse is lit!!!
Yes ...
... you're with the wrong broker (E-Trade here).
Part of another ...
... PSC email just in:
"IDCN is going to be in focus all next week for PSC."
PIE ...
... you're quite welcome ... and thank YOU for your thoughtfulness and grateful appreciation. I second your feelings toward all our troops - wherever and whomever they are - and this great country of ours.
Thanks also for the "Hoo-Yah" link ... origin? ... ya got ME ... I only know I learned to say it in my sleep ... the few times I slept! LOL
Regarding EVRN ... nobody likes dilution, but I have faith here, and look to a positive future. Good luck to you and all EVRN believers!
Okay ... okay ...
... you're all correct, EVRN is a POS and going nowhere. Navy SEAL's don't do their DD like they should anyway, they're nut cases to begin with!
I GIVE UP!!! ... gonna sell my 4MM shares now, pack some C-4 up my patoota and end it ALL!
Everybody happy now?!
Come on, Hammer ...
... you already know I can't PM. Why not just sell your shares and move on ... tryin to save us all?! RIGHT! LOL
Whiners!!! ... LOL ... Sell me your shares!!!
You were saying josh?! ... LOL
Now THAT is what I was wondering!
A Tweet isn't a promotion.
From Twitter site moments ago ...
"Stockchaser - PSC is snapping up IDCN shares. The pot is boiling, there is gonna be some big money made here."
19 minutes ago via web
CHINA PATENT! ...
Generex Subsidiary Antigen Express Receives Patent in China for Its Ii-Key Peptide Vaccine Technology
Mar 2, 2010 09:30:32 (ET)
WORCESTER, Mass., Mar 2, 2010 (GlobeNewswire via COMTEX) -- Generex Biotechnology Corporation (GNBT, Trade ) ( www.generex.com ) today announced that it has received notice of issuance of a patent in respect of its Ii-Key peptide vaccine technology in China. This expands a solid intellectual property estate that includes both broad claims covering its platform technologies as well as specific Ii-Key-containing drug development compounds. Additionally, management is actively seeking potential joint venture/licensing partnerships for its peptide cancer vaccine technology platform and is in active discussions with several large pharmaceutical companies in that respect.
The Company recently reported interim results from a Phase II trial of an Ii-Key modified peptide vaccine for patients treated for breast cancer who are at high risk of relapse. While there was a 7% relapse rate in the control arm, there were no relapses in the Ii-Key peptide arm (AE37) when analyzed at the 13-month time point. A review article co-authored by Dr. Eric von Hofe, Ph.D., President of Antigen Express, entitled "A New Era in Anticancer Peptide Vaccines", currently appears in the journal Cancer, the International Interdisciplinary Journal published by the American Cancer Society.
Anna Gluskin, President and Chief Executive Officer of Generex, stated: "We are pleased to have received this broad based patent in China for this important peptide vaccine technology. We believe the recently published results from our Phase II breast cancer study demonstrate the enormous potential our platform has for the treatment of this disease. We have begun active discussions with pharmaceutical companies for potential joint ventures and licensing agreements to significantly further our commercialization efforts in this area. We are confident that, with the right partnerships, this technology can have a far reaching positive impact on the treatment of many types of cancers and we intend to aggressively pursue our goal of bringing these platform technologies to the commercialization stage."
About Generex Biotechnology Corporation
Generex is engaged in the research, development and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. The Company's flagship product, oral insulin (Generex Oral-lyn(TM)), which is available for sale in India, Lebanon, Algeria, and Ecuador for the treatment of subjects with Type-1 and Type-2 diabetes, is in Phase III clinical trials at several sites around the world. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases. For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com .
The Generex Biotechnology Corp. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3831
Safe Harbor Statement
This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects," or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: Generex Biotechnology Corp.
CONTACT: American Capital Ventures, Inc.
Investor Relations Contact:
Howard Gostfrand
1-877-918-0774
Beckerman Public Relations
Media Contact:
Christina Brozek
201-465-8002
Shareholder Update: BioCentric Energy Holdings, Inc.
7:01 AM ET 3/1/10 | Marketwire
BioCentric Energy Holdings, Inc. (PINKSHEETS: BEHL)
The first annual BioCentric Energy Holdings annual shareholders Meeting conducted by the current Board of Directors was held on Wednesday, February 24th, 2010 at the Monte Carlo Hotel, Las Vegas, Nevada. The following quote from the meeting was issued by Dennis Fisher, Chairman of the Board of BioCentric Energy.
"I know what we, the Team of BioCentric have created... What we have designed and are implementing... The first of its kind... A remotely operated, completely automated, low cost closed loop Photobioreactor system. We have done this by way of a combination of professionals and an advanced scientific team who think and plan outside of the box. My sincere thanks and gratitude are extended to them and our partners herein. This task was accomplished with major assistance for the Version 3 upgrade to reality, by our friends and Joint Venture associates from South Carolina... Renewed World Energies.
BECO Laboratories has delivered engineering and the manufacture of exclusive components for testing and functionality. Zenxin for multiple design modifications, engineering feasibility reviews, and ongoing further modifications for the next 10,000 turns critical to our exclusive system.
Our thanks further extend to Algae Ventures for their efforts to date for an inexpensive harvesting solution and the trust they bestowed upon us in availing their engineering to our enhancements along with Shannon Plastics who have consistently used conception outside of the box to deliver one off material components.
NAA President - Barry Cohen who referred to our Algae Pro Photobioreactor solution as the 'Wal-Mart' of PhotoBioreactors. Our first client for Omega 3 with EPA, who signed before we were operational. And last but not least, Siemens for the PLC, with training and support globally to monitor and maintain the variables dictated and remotely change to optimize. It is a combination solution that utilizes the talents of many to achieve our desired results. Teamwork... is the ability to work as a group towards a common vision. It is undoubtedly because of this teamwork... here is where we are today."
BioCentric Energy Holdings (PINKSHEETS: BEHL) is a publicly held company that designs, manufactures and sells commercial Closed-Loop Photobioreactor systems and innovative algae culturing equipment. Our Equipment and Monitoring System The BioCentric Energy's commercial Closed-Loop Photobioreactor system is complete with a state of the art, highly intuitive remote, computerized monitoring control system.
Given the multitude of vital requirements for growing mass quantities of contaminant free algae, only the highest quality and most reliable CPU (Central Processing Unit) and sensors would be acceptable. Each BioCentric Energy Closed-Loop Photobioreactor system utilizes the preprogrammed Siemens (PLC) sensors that receive data from the CPU to adjust the systems temperature, PH levels, growth, nutrients, water, turbidity and several other vital elements.
BioCentric Energy's Primary Objectives for the Next 90 Days are:
1. Website updates
2. Complete new laboratory in SA
3. Complete our 6500 sq ft version 3 PBRs in Santa Ana
4. Complete exact same version, 6500 sq ft version 3 PBRs in SC
5. Assemble hard asset components to Lone Star College for a small 4300 sq ft PBRs and begin the assembly process
6. Locate and secure 150 + acres for multiple client farms at one California location
7. Informing in detail our newly appointed CEO with all major future BioCentric objectives
8. Completion of the $5M Capital raise
9. Complete Form 10 filing to OTC: BB requirements
10. Complete the sale of 3 inoculants reactors
11. Sell two continuous flow desktop reactors
12. Submit three provisional patents already proven by the company.
13. Hire an independent evaluator to ascertain today's perceived value on provisional patents already received by US Patent Office
Achievable goals for the next 6 months:
1. Complete two acres on our 150+ acre site
2. Sign three clients to our 150 site
3. Sign one client for a 10 acre build at their location
4. Solicit and bring in additional omega 3 contracts
5. Finalize first Solutions 28 contract
6. Sell 3 innoculant reactors
7. Sell two continuous flow desktop reactors
8. Complete Lone Star College 4300 sq ft PBRs and begin the validation process
Projected year 2011 obtainable objectives:
1. Our goal is to have 25 acres up, running, and optimized before the next shareholders meeting
2. To complete the assembly plant to stencil out our "Two twenty foot containers for each acre" facility
3. To begin the up listing process to advance to the NASDAQ exchange
Projected year 2012... our achievable goals are as follows:
1. We are the number one supplier of closed loop Photobioreactors on the planet with over 200 acres installed, operational, and optimized for maximum productivity
2. We are a NASDAQ company
3. We are a premiere acquisition target
4. We all have earned our way to significant profitability"
Additional News:
The National Algae Association (NAA) West Coast Chapter Workshop held at the Monte Carlo Hotel and Casino in Las Vegas, February 25th - 26th was an immense success. The comments received to date include "extremely informative," to "the most enlightening and educational algae forum to date," to "a truly edifying experience in my pursuit of knowledge on algae." Monique Barry deserves special recognition for her tireless efforts to deliver a quality, professional and an interesting workshop in which all participants seemed genuinely pleased with the results. Lisa Cohen and Patrick Kuydehal also deserve mention for their participation in accomplishing such a successful interaction.
View this release in video format:
http://www.vodnewswire.com/vodnewswire/news/biocentric-energy-20100301/
Safe Harbor Statement: This release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by phrases such as BEHL or its management "believes," "expects," "anticipates," "foresees," "forecasts," "estimates" or other words or phrases of similar import. Similarly, statements herein that describe the Company's business strategy, outlook, objectives, plans, intentions or goals also are forward-looking statements.
All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.
Contact:
Monique Berry
Executive Vice President
BioCentric Energy
714-966-1234
Website: www.Biocentricenergy.com
SOURCE: BioCentric Energy Holdings, Inc.
http://www.biocentricenergy.com/
I know, Cisco ...
... doesn't make sense to me either ... but ... they may survive on website advertising. I have another stock (KLYG) that also posted here, and their corporate is so tight they squeak!
Correct ...
... and that very paragraph ALSO says Any compensation is listed in the disclaimer/compensation section located at the bottom of every page.
Exactly, outperformers ...
... not sure where livinginstyle is getting his incorrect information.
Uhhh ... livinginstyle ...
... wrong again, I'm afraid. Here's the link to the Disclaimer/Compensation page on the website, at the very bottom of the homepage.
http://www.stockprofile.com/disclaimer.php
The 6th company down from the top is IDCN, which shows 12-months FREE ....
Indocan Resources, Inc. 02/22/2010 12 Months Free None Jeffrey R Bruhjell
Uhhh ... livinginstyle ...
... you say "The company paid to be profiled on that site.", i.e. Stockprofile.com.
Show me where it says that IDCN paid for the stock promotion.
Calm before the storm here?
StockProfile.com email received ...
Dear Subscriber:
We are pleased to inform you that the following company has been added to the Company Profile roster at StockProfile.com:
Indocan Resources, Inc. (IDCN)
Can you spell REVENUE ??!!
56MM+ traded in first 15 minutes.
Get $.0009's and you're a THIEF!
Bargain Basement Prices!
Website News Update ...
19 Feb 2010--Funding efforts for our subsidiary, Sierra Cora Ltd., are yielding fruit now and we expect a successful conclusion to these activities in the coming weeks. Sampling work will occur shortly in NW Ontario and a comprehensive plan is being designed by geology.
http://www.indocan.com/frontpage.html
It was a gift.
Mardi Gras hangover.
Amen.
I like the "filed" part.
$.0009 ... what a STEAL!!!
It doesn't matter ...
... load, load and load some more.
7 rows ...
... of $.0010 ... time to back up the truck.
One of those ...
... sloooooooooooooooooooooow burning fuses.
Float gettin' tight??
That's ...
... alot of $.0010's ... be nice to snag some more. :)
IDCN Website Update ...
I don't know if this had been posted earlier or not.
"17 Feb 2010--Yes, we are going to re-enter the oil patch soon but must first fund our subsidiary, Sierra Cora Ltd. and provide cash for the winter sampling program. We will either make another subsidiary or use Sierra Cora for an oil field investment."
http://www.indocan.com/frontpage.html
... slow and steady wins the race.